CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

How Biotech Startups can Mitigate Risks in Order to Grow Sustainably

How Biotech Startups can Mitigate...

Vivid Microscopy Detects Early Stages of Heart Disease Using an Animal Model

Vivid Microscopy Detects Early Stages...

How Contract Manufacturing Benefitting Small Businesses

How Contract Manufacturing...

Top Biotech Industry Trends to Watch for in 2022

Top Biotech Industry Trends to Watch...

European Life Sciences Off to a New Beginning

European Life Sciences Off to a New...

Encore Healthcare's VP of Clinical Operations Carrie Hylton-Proffitt, RRT Earns Accreditation with ACHC

Encore Healthcare's VP of Clinical...

Challenges Facing Biotech Companies Seeking Funding

Challenges Facing Biotech Companies...

How are Advancements in Biotechnology Help People Improve their Lives?

How are Advancements in Biotechnology...

How Biotech Startups can Mitigate Risks in Order to Grow Sustainably

How Biotech Startups can Mitigate...

Vivid Microscopy Detects Early Stages of Heart Disease Using an Animal Model

Vivid Microscopy Detects Early Stages...

How Contract Manufacturing Benefitting Small Businesses

How Contract Manufacturing...

Top Biotech Industry Trends to Watch for in 2022

Top Biotech Industry Trends to Watch...

European Life Sciences Off to a New Beginning

European Life Sciences Off to a New...

Encore Healthcare's VP of Clinical Operations Carrie Hylton-Proffitt, RRT Earns Accreditation with ACHC

Encore Healthcare's VP of Clinical...

Challenges Facing Biotech Companies Seeking Funding

Challenges Facing Biotech Companies...

How are Advancements in Biotechnology Help People Improve their Lives?

How are Advancements in Biotechnology...

Sana Biotechnology Signs a Long-Term Lease to Establish a Manufacturing Facility for Manufacturing Gene and Cell Therapy Product Candidates

Life Sciences Review Life Sciences Review | Tuesday, July 27, 2021
Tweet

Sana Biotechnology, Inc. enters into a lease agreement to construct a 163,000-square-foot manufacturing facility in Fremont, California.


FREMONT, CA: Sana Biotechnology, Inc., a business focused on developing and commercializing modified cells as pharmaceuticals, signs a leasing agreement to create a 163,000-square-foot manufacturing facility in Fremont, California. This facility will be used to manufacture Sana's late-stage clinical development and early commercial product candidates across the company's diverse technology platforms.


“Manufacturing remains a key bottleneck to the development and broad accessibility of cell- and gene-based medicines. This facility is a key component in enabling our aspirations to rapidly innovate, consistently manufacture, and scale production of these medicines,” says Steve Harr, Sana's President and CEO. “Sana is making significant investments to create the scientific insights, supply chain stability, and operational capabilities to transform the potentially disruptive scientific insights of the cell and gene therapy field into important medicines for patients.”


The Fremont location puts Sana's existing technical and scientific capabilities within easy reach and provides access to a strong biotechnology talent pool. The facility produces allogeneic T cells, viral vectors, and pluripotent stem cells. Sana also wants to cooperate with contract manufacturing partners to push its product candidates to the clinic as early as next year, as part of the company's holistic manufacturing approach.


Sana Biotechnology, Inc.'s mission is to develop and distribute modified cells to patients as medications. We share a vision of repairing and managing genes, replacing missing or damaged cells, and disseminating our remedies. We are a team of over 300 people dedicated to building an enduring company that transforms how the world addresses disease. Sana operates out of Seattle, Cambridge, and San Francisco's South Bay.


Weekly Brief

loading
Top 10 Biotech Startups Companies - 2022
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

Prophesying DNA Sequencing for 2023

Crucial Workflows of Next-Generation Sequencing

An Overview of Next-Generation Sequencing

The Role of AI in Accurate Medical Writing

Patrik Renblad to Join Cantargia as Chief Financial Officer

Overview of the Life Sciences BPO Market

Dr. Zamaneh Mikhak Joins TFF Pharmaceutical as the New Chief Medical Officer

The Significance of AI in Medical Writing

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/sana-biotechnology-signs-a-longterm-lease-to-establish-a-manufacturing-facility-for-manufacturing-gene-and-cell-therapy-product-candidates-nwid-466.html